Innovation says Wang Pharmaceuticals is laying off workers... 2021 These pharmaceutical policies still need to be noted!

2020 is still a big year for pharmaceutical policy.
Looking back, the reform of the "three-doctor linkage" has been deepening, with the medical insurance bureau's procurement and use as a breakthrough to deepen medical reform, profoundly affecting the whole pharmaceutical industry chain, while the medical insurance catalog adjustment structure and innovative drug access negotiations normal, the entire pharmaceutical market "space, adjustment structure" is accelerating day by day.
data show that the cost savings of the three batches of drugs are 53.9 billion yuan, and the collection of crown braces is expected to save 11.7 billion yuan.
health insurance catalog "Cage for Bird", payment structure tends to innovate drugs, innovation and high-quality innovation has become the core competitiveness of pharmaceutical companies, but also the main line of market investment.
2020, the basic drug catalog, health care payment reform, Internet health care and other policies have ushered in some adjustments and changes.
huge structural fission in that is, enterprise layoffs, product line optimization frequently, but also sell assets focus on the main industry cold-safe ... Wind and clouds, big waves, who can be tomorrow's winner? Waved from Z, Xiao Xiaoban Maming.
these policies will still need to be noted by the medical public in 2021.
band procurement: drugs, consumables collection on the formation of 1. Drug collection twice a year, towards the beginning of normalization in 2020, the second round of drug national tenders, involving a total of 33 varieties, covering diabetes, hypertension, anti-tumor and rare diseases and other therapeutic areas, the average price reduction of this collection reached 53%, the highest decline of 93%.
especially the sugar-lowering drug acapospose, gremethyl and other chronic diseases commonly used drugs.
82% for foreign-funded original drugs and 51% for generic drugs.
the second half of 2020, the third batch of drugs will follow, continue to continue the bidding idea.
August 24, the Shanghai Joint Procurement Office issued the third batch of national centralized belt procurement results, in addition to Ramif fixed flow mark, the remaining 55 generic name varieties successfully winning the bid.
the average price reduction of 53%, of which the stone drug European-Italian Meso-King Kong fell the most, to 98.7%.
year, the future direction of drug harvesting began to become more and more clear.
The industry out of 500 procurement amount is high, the use of large quantities of drugs will be in 3 years by the national harvest, provincial collection of all cover, with volume procurement is expected to be carried out twice a year, not only chemical drugs, bio-similar drugs, insulin, etc. will gradually carry out collection, in addition to injection consistency evaluation work has also been started.
market competition is full, the relevant rules are issued, China's pharmaceutical industry structure will be significantly changed, generic drug market reshuffle, import substitution accelerated.
the end of the year, on December 25, Shanghai Sunshine Pharmaceutical Procurement Network issued the fourth batch of information declaration work notice, the fourth batch of collection work officially began.
44 drugs, 90 products selected, involving cancer, diabetes, hypertension, anti-infection, breathing, digestion and other fields.
Based on the first batch of "4 plus 7" with volume procurement, "4 plus 7" expansion, as well as the second and third batch of collection average decline of more than 50%, the industry forecast next year to open the fourth batch of national procurement, the average price of drugs will also fall by more than half.
analysts believe that the normalization of drug collection will lead to the reconstruction of drug competition pattern, can accelerate the domestic substitution of imported drug enterprises dominated varieties, and create market opportunities for domestic pharmaceutical enterprises.
, a number of inferior, homogenized development of generic drug companies will also be quickly withdrawn, the valuation of related enterprises will also be adjusted.
the other side, pharmaceutical giants are busy laying off workers, optimizing product lines, and small businesses are selling capital for the winter.... It really confirms that sentence, the only thing that doesn't change is change.
2. Heart stents hit the first shot of supplies collection, orthopaedic batons and drugs, medical supplies are also the worst-hit areas of medical corruption.
With the experience of drug national harvesting, after the national multi-site pilot on the basis of this year's high-value supplies country picked the first shot, the first single aim has been the leading role of clinical abuse has been repeatedly banned - coronary stent, that is, heart stent, stent product circulation in the price of water, industry insiders said that through collection can play a role in reducing prices, saving health insurance funds.
October 16th, the Joint Procurement Office of High Value Medical Supplies of The National Organization issued a notice on the "National Organization Crown Bracket Centralized Band Procurement Document (GH-HD2020-1)."
This round involves 27 coronary stents, such as coronary repamycin el-equip cobalt-based alloy stent system, drug stent system, ivemos elo-coronary artery stent system, etc., with a centralized band procurement cycle of 2 years.
November 5, the results of the national organization's crown stent centralized belt procurement were announced.
10 products from eight companies are to be selected.
selected enterprises include Shandong Jiwei, Yisheng Technology, Minimally Invasive Medical, Lepu Medical, Medtrol, Shenzhen Jinrui Kelly, Boston Science, Wan Ruifeihong.
average price of the crown vein bracket fell from about 13,000 yuan to about 700 yuan, an average decrease of 93% compared to 2019, and is expected to save 10.9 billion yuan in terms of intentional purchase volume.
prices such as Minions and Lepu fluctuated due to lower-than-expected prices.
And according to Sina Pharma from people familiar with the situation, affected by the first batch of consumables collection, Medtron intends to lay off 200 people, mainly in the logistics and support departments;
the end of the first batch of crown-pulse bracket national mining, the second batch of high-value consumables national mining documents also followed closely.
November 24, a second batch of high-value consumables collection red head documents circulated in the circle, the document shows that the second batch of centralized procurement data rapid collection involving six categories: artificial hip joints, artificial knee joints, defibrillators, blockers, orthopaedic materials, matching devices six kinds of high-value supplies. shortly after the
, on December 18, Sichuan Province issued a notice, announced the second batch of high-value supplies related products in Sichuan declared the list of enterprises, and asked Medtron, Johnson and Johnson, Abbott, Minimally Invasive, Weisheng 258 enterprises by December 27 to complete the basic information filling and matching of related products, involving health insurance coding and other key content.
, like coronary stents, orthopaedic supplies are medical supplies with high clinical use and relatively high prices.
china's orthopaedic supplies market is mainly dominated by Johnson and Johnson, Medtron and other foreign manufacturers, domestic brands are not prominent.
national collection will accelerate the market pattern changes, domestic orthopaedic supplies brand market share is expected to increase.
it is expected that consumables enterprises to lay off workers, optimize the structure of the department, etc. will also be the norm.
health care catalog: where there is a need to talk about, opening a green channel for innovative drugs 2020 on the health care catalog adjustment of any wind and grass movement is moving.
29 April, the State Health Insurance Administration issued the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (Draft for Comments), which for the first time established the procedure for the adjustment of the medical insurance catalogue, which in principle is adjusted once a year.
and regulations have been made for the transfer-in and transfer-out of the drug.
, the NHS will continue to negotiate or bid for access in the next dynamic adjustment of the health-care directory.
same time, industry sources said, the document also revealed that the new adjustment into the catalog of drugs will certainly negotiate, or participate in the national collection, that is, "all into the must talk (picking)."
the scope of the adjustment includes new products (generic names, dosage forms and adaptive disorders) approved in the first two years of the catalog.
August 17, the National Health Insurance Administration officially issued two documents, the 2020 National Health Insurance Drug Catalog Adjustment Work Programme and the 2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines.
is noteworthy that new drugs explicitly included in the work programme need to be approved for market by 17 August 2020, unlike the "drug market deadline of 31 December 2019" mentioned in the previously published draft.
the NHS's intention to encourage new drugs is clear.
28, 2020, the new version of the health care directory was officially released.
the total number of drugs in this adjusted catalogue is 2800, of which 1426 are Western medicines and 1374 are Chinese medicines.
chinese medicine tablets in the catalogue were not adjusted and remained at 892.
, a total of 119 drugs were successfully negotiated, of which 96 were successfully negotiated outside the catalogue and 23 were successfully negotiated in the catalogue.
success rate of the negotiations was 73.46 per cent.
prices for drugs negotiated in the united States have been reduced by an average of 50.64 per cent.
anti-cancer drugs are still the hot spot in this adjustment, a number of star anti-cancer drugs to reduce prices.
17 cancer drugs were successfully listed through negotiations in 2018 and the agreement expires at the end of 2020, according to the National Health Insurance Administration.
of the 17 anti-cancer drugs, three generic drugs were listed in Class B management.
14 exclusive drugs were renewed or renegotied on a rule-by-rule basis, with an average decline of 14.95 per cent, with individual first-line cancer drugs falling by more than 60 per cent.
estimates, 14 anti-cancer drugs reduced prices, is expected to save cancer patients more than 3 billion yuan by 2021.
this adjustment also added 17 anti-cancer drugs, including PD-1, lenvatini, etc.
years, Our country is constantly exploring and perfecting the mechanism of medical insurance negotiation.
five groups of negotiations since 2015.
health care negotiations are expected to take place every year, the health insurance catalog dynamic adjustment mechanism set up, a step closer to the good innovative drugs.
a batch of drugs of low clinical value will also be kicked out to make way for new drugs.
of the drug catalog: "God medicine" accelerated out, high-priced drugs are expected to be included on the other side, the base drug catalog adjustment news is also spread in 2020.
China began to implement the base drug catalog system in 2009, the number of drugs covered since then has been expanding, the 2009 version of only 307, to the 2013 version expanded to 520, the 2018 edition was expanded to 685.
July 14, 2020, relevant departments held a meeting on the related issues of base drugs, and clearly plan to update and revise the current 2015 version of the base drug catalog management methods.
the minutes of the meeting pointed out that the adjustment cycle of the base drug is still three years, the dynamic adjustment of each year, the base drug positioning remains unchanged.
in terms of time, the base drug catalog will be adjusted on a large scale by 2021.
in the adjustment principle, it is expected that "God medicine" will accelerate the exit, clinical value of high new drugs, evaluation of generic drugs will be reused.
also mentioned that the base drug will be combined with the chronically ill long prescription to establish a list of the core drug use of the base drug.
October 15, the National Conference on The Drug System was held in Chongqing, and representatives of Taiji Group, Watson Pharmaceuticals, Zhifei Bio, Colum Pharmaceuticals, Pfizer, AstraZeneta and other pharmaceutical companies were invited to attend.
, the relevant ministries have made it clear that the base drug is not equal to low-cost drugs, clinical value of high-priced drugs can also be considered for inclusion in the list of base drugs.
, the base drug adjustment will not consider the enterprise's active declaration, will be the selection of clinical experts mainly.
, november 16th, the national approach to the management of base drugs for comments and discussions on the minutes of the meeting circulated in the industry.
The focus of the adjustment of the base drug in 2021 includes: 1, infectious diseases, 2, chronic diseases and cancer, tumor slow disease medication, 3, common disease medication, 4, disease-oriented direction, it is true that patients are not available, need to be treated, to choose the most appropriate range; 5, mainly look at product value, clinical endpoint indicators, can improve the long-term quality of life of patients, can be cured as a standard.
noteworthy, the participants suggested that the number of base drug catalogue expansion can reach 90%, 80%, 60% hospital staffing requirements, and the number of base drugs 900 to meet the policy requirements.
2021, the adjustment of the base drug catalogue will also be a big point of view.
health care payment reform: left-handed DRG, right-handed DIP 2019, the National Health Insurance Administration identified 30 cities to carry out disease diagnosis-related sub-groups (DRGs) payment pilot.
2020, drG pay reform pilot work has gradually been on track.
June 18, the National Health Insurance Administration issued a notice on the Health Care Security Disease Diagnosis Subgroup (CHS-DRG) Subgroup Program (version 1.0).
CHS-DRG subdivision group is a further refinement of the 376 core DRGs (ADRG) of the National Health Care DRG Subgroup Program, and is the basic unit of DRG payment, with a total of 618 groups.
for the health-care sector, the reform would make health-care purchase negotiations and financial balance more efficient by focusing on patients and making health-care funds more efficient.
with the deepening of DRG reform, coupled with the superimposing effect of volume procurement, enterprises will face the future hospital drug use and drug use amount of the "double-down" situation.
in the process of exploring the reform of health insurance payment, in addition to DRG payment, China has also developed a more in line with the national conditions of the disease-based pay-per-view (DIP) method.
On October 19th, the State Health Insurance Administration issued the Pilot Work Programme on the Total Budget of the Regional Points Law and Paying by The Value of Diseases, which clearly carried out the pilot work on the basis of the district-level municipal co-ordination zones, combining the total regional medical insurance budget with the points method in 1-2 years' time, so as to realize the multi-composite payment method based on the value-added payment of diseases in hospitals, and by the end of 2021, all regions will have entered the actual payment phase.
3rd, the National Health Insurance Administration issued a total budget for the regional points method and a list of pilot cities that pay for disease-based points.
71 cities in 27 provinces were selected.
November 20, the State Health Insurance Administration issued the Notice on the Issue of the Technical Specifications for the Payment of National Health Insurance by Disease Score (DIP) and the DIP Disease Directory (version 1.0).
the introduction of DIP technical specifications and catalog libraries, providing important technical guidance and support for the pilot cities.
December 14, the National Health Insurance Administration released the 2021 DRG paid national pilot experts fixed contact sub-group list, requiring pilot cities to strengthen communication with experts ... DIP based on the whole sample data diagnosis and operation of automatic grouping, which was born in DRGs, simpler management, is suitable for most parts of China's national conditions of the payment method.
THE DIP landing will force hospitals to make rational use of medical resources, limit over-medical treatment, is a further step of medical insurance